Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobio Pharmaceuticals Group CoJBPHF 33 Equity-to-Asset is 0.59 as of Dec. 2025, which is 17% below its 10-year median of 0.71. GuruFocus rates JBPHF with a GF Score™ of 33/100 and a GF Value™ of $0.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,415 Biotechnology companies, Jacobio Pharmaceuticals Group Co ranks worse than 59.72% on this metric.
The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's Equity-to-Asset or its related term are showing as below:
JBPHF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.29 Med: 0.71 Max: 0.96
Current: 0.59
During the past 8 years, the highest Equity to Asset Ratio of Jacobio Pharmaceuticals Group Co was 0.96. The lowest was -1.29. And the median was 0.71.
JBPHF's Equity-to-Asset is ranked worse than 59.72% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs JBPHF: 0.59
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Jacobio Pharmaceuticals Group Co Equity-to-Asset Related Terms
Jacobio Pharmaceuticals Group Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Equity-to-Asset Chart
JBPHF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Equity-to-Asset falls into.
Jacobio Pharmaceuticals Group Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a Equity-to-Asset of 0.59 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. This is 17% below median its historical median of 0.71. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #845 out of 1415 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Jacobio Pharmaceuticals Group Co's Equity-to-Asset too high?
Jacobio Pharmaceuticals Group Co's current Equity-to-Asset of 0.59 is 17% below median its 10-year median of 0.71. The Biotechnology industry median Equity-to-Asset is 0.68. Jacobio Pharmaceuticals Group Co's value of 0.59 is 13.2% below this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #845 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #845 out of 1415 companies for Equity-to-Asset. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Jacobio Pharmaceuticals Group Co's value of 0.59 is 13.2% below this benchmark. While the company's 10-year median is 0.71 vs. the industry median of 0.68, Jacobio Pharmaceuticals Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Equity-to-Asset of 0.59 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Equity-to-Asset is 0.59, which is 17% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.30, compared to a current price of $0.64 — trading 113.4% above its estimated fair value. The current Equity-to-Asset is 0.59, which is 17% below median its 10-year median of 0.71 and 13.2% below the Biotechnology industry median of 0.68. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Equity-to-Asset is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.64 is trading 113.4% above its estimated GF Value™ of $0.30.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.
Key valuation signals for JBPHF:
Equity-to-Asset: 0.59 (17% below median its 10-year median of 0.71)
GF Value™: $0.30 vs. price of $0.64 (113.4% above fair value)
Industry Position: 13.2% below the Biotechnology median (#845 of 1415)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
33GF Score
Get the complete analysis for JBPHF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
